ArticleInflammatory bowel diseases2025
Endoscopic Recurrence in Crohn's Disease Patients With Long-Term Ileostomy.
Article in Inflammatory bowel diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA small but significant proportion of patients with Crohn's disease (CD) will ultimately require a permanent ileostomy. So far, research has focused primarily on clinical and surgical recurrence rates in the ileum, leaving endoscopic recurrence largely unexplored. The aim of this study was to explore the endoscopic ileal recurrence rate in patients with a long-term ileostomy and to identify potential risk factors.
methodsWe performed a retrospective study of adult CD patients with a long-term ileostomy (≥12 months) at a tertiary referral center.
resultsThrough an electronic health record database search, we were able to identify 150 patients. One hundred sixteen patients (77.3%) underwent at least one endoscopic examination of the ileum. Ileal recurrence was detected in 46/116 (39.7%). The 1, 3, and 5-year endoscopic recurrence rates were 11.2%, 27.3%, and 33.0%, respectively. Patients with earlier ileal involvement (hazard ratio [HR] 1.99, 95% confidence interval [CI] 1.09-3.62; P = .02) or previous biological therapy (HR 2.48, 95% CI 1.25-4.89; P = .01) were at higher risk. Fecal calprotectin in ileostomy effluent accurately predicted endoscopic inflammation at a cutoff of 170 mcg/g (sensitivity 77.8%, specificity 94.7%, accuracy 89.9%).
conclusionsIn this retrospective study, 77.3% of ileostomy patients underwent endoscopic assessment during follow-up. Ileal recurrence was detected in 39.7% of patients who underwent endoscopic evaluation. Patients with ileal involvement or preoperative exposure to biologics had the highest risk of recurrence. These patients might benefit from endoscopic monitoring. Fecal calprotectin is a reliable noninvasive marker for detecting ileal inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.